First Clinical Trial to Test PrEP, Dapivirine Ring for Safety in Pregnant Women Begins
February 20th 2020The study, called DELIVER: A Phase 3b Safety Study of the Dapivirine Ring and PrEP in Pregnant Women, will complement an ongoing NIH-funded trial of PrEP in adolescents and young women during pregnancy and the first 6 months after birth.
Read More
New Diabetes Drug Combination Induces High Rates of Human Beta Cell Regeneration
February 20th 2020When combining a drug that is known to cause beta cells to proliferate with another drug that is already in widespread use in people with diabetes, it will cause the cells to proliferate at a rate of 5% to 6% per day, according to the study authors.
Read More
Politicians on both sides of the aisle have long been debating key issues in modern health care, including rising drug prices, access to care, and national addiction rates. Despite some agreement on which issues are most pressing, arguments persist in how to address them heading into the 2020 presidential election.
Read More
Tracking the Shift in Health Insurance from Conventional Coverage to High Deductible Plans
February 19th 2020Over the past 30 years, health plans have changed from primarily conventional health care coverage to alternatives such as health maintenance organizations and, most recently, high deductible health plans.
Read More
Report: Many Opportunities for Health System Pharmacy Growth, Potential Risks Over Next Decade
February 19th 2020Pharmacists are the primary drivers of their destiny, according to a new report, and they will continue to drive change in the industry by demonstrating their value, securing compensation, and advocating for expanded roles.
Read More
FDA Approves Topical Arthritis Pain Reliever for Nonprescription Use
February 18th 2020Diclofenac sodium topical gel was first approved by the FDA in 2007 as a prescription drug, and was indicated for the relief of osteoarthritis pain in joints responsive to topical treatment, particularly the joints of the hands, knees, and feet.
Read More
In the pivotal phase 3 KEYNOTE-355 study, pembrolizumab (Keytruda, Merck) combined with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed programmed death-ligand 1 (PD-L1).
Read More